By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


PTC Therapeutics, Inc. 

100 Corporate Court

South Plainfield  New Jersey  07080-2449  U.S.A.
Phone: 908-222-7000 Fax: 908-222-7231


Drug Discovery

Company News
PTC Therapeutics (PTCT) Release: Phase 2 Data From Spinal Muscular Atrophy Program To Be Presented At The 20th International Annual Congress Of The World Muscle Society 10/5/2015 6:49:45 AM
PTC Therapeutics (PTCT) Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 10/5/2015 6:32:59 AM
PTC Therapeutics (PTCT) Submits European Application For Translarna For Cystic Fibrosis 9/30/2015 7:19:34 AM
Health Canada Initiates Review Of PTC Therapeutics (PTCT)' New Drug Submission For Translarna For The Treatment Of Duchenne Muscular Dystrophy 9/18/2015 8:13:03 AM
PTC Therapeutics (PTCT) Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 9/4/2015 7:56:11 AM
PTC Therapeutics (PTCT) Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 8/24/2015 6:35:03 AM
PTC Therapeutics (PTCT) Announces Closing Of $150 Million Of Convertible Senior Notes 8/17/2015 6:36:52 AM
PTC Therapeutics (PTCT) Announces Pricing of $125 Million Of Convertible Senior Notes 8/11/2015 7:31:40 AM
PTC Therapeutics (PTCT) Announces Intention To Offer Convertible Senior Notes 8/11/2015 7:30:24 AM
PTC Therapeutics (PTCT) Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/3/2015 7:07:28 AM